Skip Navigation U.S. Department of Health and Human Services
Agency for Healthcare Research Quality
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to for current information.

Figure 1. Drug Nonadherence in 2003 among Medicare Beneficiaries Receiving Drugs of the Same Class in 2002

Bar chart shows percentage of Medicare beneficiaries receiving certain types of drugs and compares those whose benefits were capped versus those whose benefits were not capped.  Antihypertensive: Benefits capped, 18.1%; Benefits not capped, 14.6%. Lipid-lowering Drugs: Benefits capped, 31.4%; Benefits not capped, 26.5%.  Antidiabetic: Benefits capped, 26.2%; Benefits not capped, 21.2%.

Source: Unintended consequences of caps on Medicare drug benefits, by John Hsu, M.D., M.B.A., M.S.C.E., Mary Price, M.A., Jie Huang, Ph.D., and others, in the June 1, 2006, New England Journal of Medicine 354:2349-59.

Return to Document


The information on this page is archived and provided for reference purposes only.


AHRQ Advancing Excellence in Health Care